Tasigna Emerging Litigation
Tasigna by Novartis AG
Tasigna (NILOTINIB HYDROCHLORIDE MONOHYDRATE) made by Novartis gained FDA approval in October 2007, New Drug Application (NDA: 022068)
Tasigna is FDA approved for the treatment of accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia in adult patients resistant to or intolerant to prior therapy.
Unwarned adverse events potentially associated with Tasigna include accelerated atherosclerosis. This life-threatening condition occurs when plaque accumulates in the arteries. As plague builds up in the arteries, a reduction in blood flow can occur, resulting in a large number of secondary conditions which in some cases can lead to death.
How to Learn More About the Emerging Tasigna Litigation
The emerging Tasgina Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” to register for the May Course, contact Jenny Levine at email@example.com or call (954) 520-4494.
For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”
Course attendees will receive the benefit of a step by step analysis of the emerging Tasigna Litigation, using these primary metrics:
See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>